Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer
|
|
- Gloria Houston
- 6 years ago
- Views:
Transcription
1 Original article Annals of Oncology 16: , 25 doi:1.193/annonc/mdi275 Published online 9 June 25 Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer W. Irish 1 *, B. Sherrill 1, B. Cole 2, C. Gard 3, G. A. Glendenning 4 & H. Mouridsen 4 1 Research Triangle Institute, Research Triangle Park, NC; 2 Dartmouth-Hitchcock Medical Center, Lebanon, NH; 3 Novartis Pharmaceutical Corporation, East Hanover, NJ; 4 Righospitalet, Copenhagen, Denmark Received 17 January 25; revised 15 April 25; accepted 29 April 25 Background: Results from a phase III study of postmenopausal women with advanced breast cancer demonstrated longer time to disease progression for patients taking letrozole versus tamoxifen. This analysis compares the trade-offs between progression-free survival and toxicity. Design: Quality-adjusted survival was calculated using Q-TWiST (quality-adjusted time without symptoms or toxicity). Survival curves were partitioned into three health states: toxicity (TOX), disease progression (PROG) and periods without toxicity or disease progression (TWiST). The utilityweighted sum of the health state durations was derived and compared. Results: There was not a significant difference in mean duration of serious adverse events prior to progression between the letrozole (n = 453) and tamoxifen (n = 454) groups (2.2 and 2 months, respectively). For TWiST, the mean duration for letrozole was 11.5 months, versus 8.5 months for tamoxifen (P <.1). The mean duration of PROG was 11.5 months for letrozole and 12.7 months for tamoxifen (P =.47). Using utility weights of.5 for TOX and PROG resulted in a 2.5-month difference in quality-adjusted survival favoring letrozole (P <.1). Conclusions: The longer time to disease progression with letrozole versus tamoxifen was achieved without increased time with adverse events and resulted in more quality-adjusted survival for patients on letrozole. Key words: letrozole, Q-TWiST, quality-adjusted survival, tamoxifen Introduction Clinical decision-making for advanced breast cancer patients must balance the trade-offs between treatment toxicities and expected survival. The value of a treatment depends not only on absolute survival time, but also on the quality of the life of the patient during that time. Unlike classical survival analysis, the Q-TWiST (qualityadjusted time without symptoms or toxicity) approach quantitatively adjusts periods in which treatment toxicities or symptoms of disease progression are present to reflect the potentially reduced value for the patient. The methodology partitions the survival time of the patient into various health *Correspondence to: Dr W. Irish, Research Triangle Institute, 34 Cornwallis Road, PO Box 6452, Research Triangle Park, NC , USA. Tel: ; Fax: ; wirish@rti.org states, assigns utility weights to each and compares treatments based on the overall survival experience [1 6]. Previously published results from a phase III clinical trial comparing letrozole 2.5 mg with tamoxifen 2 mg in postmenopausal women with advanced breast cancer demonstrated the superiority of first-line letrozole over tamoxifen in terms of time to progression and early survival [7]. The study reported similar frequencies and types of adverse event for the two treatments. However, as is typical in reporting of clinical trial data, the duration of adverse events and whether patients experienced adverse events multiple times was not addressed. Patients were allowed to cross over to the alternate treatment after disease progression, and overall median survival was not significantly different at end of follow-up [8]. We re-analyzed the clinical trial data using the Q-TWiST approach to assess whether the impact of duration of time with and without progression, and duration and severity of toxicities resulted in differences in quality-adjusted survival. q 25 European Society for Medical Oncology
2 1459 Patients and methods Study design The data source was a double-blinded, multicenter, randomized, parallelgroup, phase III study comparing the efficacy and safety of letrozole and tamoxifen among postmenopausal women with advanced breast cancer. Detailed methods, inclusion/exclusion criteria, and efficacy and safety results are available in a previous publication by Mouridsen et al. [7, 8]. Patients were randomized to either letrozole 2.5 mg/day or tamoxifen 2 mg/day orally as monotherapy. The intention-to-treat (ITT) population included all randomized patients who took at least one dose of the assigned treatment (n = 97). First-line treatment was given until disease progression or other reason necessitated discontinuation. If a patient was eligible for further endocrine anticancer treatment, then treatment could be switched to the alternative study medication. Blinding was maintained after treatment switch, and patients were followed for overall survival. Physical examinations and complete tumor assessments were performed at baseline and every 3 months. Increases of 25% or more in lesions or the appearance of new lesions were considered evidence of disease progression. Disease progression was also considered to occur if a patient discontinued treatment with clinical deterioration, or death occurred due to breast cancer or unknown cause while receiving treatment or within 6 weeks of discontinuation. Time from randomization to disease progression (TTP) was the primary efficacy end point, and overall survival was a secondary end point. Safety was assessed through routine monitoring and recording of hematological, renal and liver function. The severity of all adverse events was designated according to the National Cancer Institute Common Toxicity Criteria. Analysis approach Health states. Overall survival time was classified into three clinical health states. (i) Toxicity (TOX): time spent with severe or life-threatening adverse events prior to disease progression. (ii) TWiST: time without toxicity of treatment or symptoms of disease progression defined as the difference between the time spent in TOX and the time to disease progression. (iii) Progression (PROG): period following disease progression ending with death or censoring. Estimates of the mean amount of time spent in each of the health states were determined separately for each treatment group, using the Kaplan Meier method. Survival curves for each treatment group corresponding to toxicity duration, disease-free survival, and overall survival within the median follow-up of 32 months were plotted on the same graph. Q-TWiST calculation Mean Q-TWiST for each treatment arm was calculated as: Q 2 TWiST ¼ðu TOX *TOXÞþTWiST þðu PROG *PROGÞ where TOX, TWiST and PROG represent the mean health state durations from Kaplan Meier analysis; u TOX and u PROG denote the utility coefficients for the states TOX and PROG, respectively. For treatment comparison purposes only, TWiST is considered to have utility equal to 1, representing the best possible quality of life for a patient with advanced breast cancer. Utility weights Utility weights (u i ) were used to reflect quality of time in each health state, relative to TWiST. Sensitivity analyses were conducted by varying the assigned utilities for TOX and PROG in.25 increments across the full range of possible utility weights from (representing poorest health) to 1 (representing utility equal to TWiST). Treatment comparisons were then made using the relative weights in a threshold utility analysis to determine which relative utility weightings resulted in significant treatment differences. Statistical analyses Differences in mean Q-TWiST between treatments were tested using a Z-test for every possible combination of utility weights. Sensitivity analyses were performed using alternate definitions of the TOX health state: (i) adverse events attributable to study drug (possible, probable or highly probable); and (ii) all adverse events regardless of severity or attribution. Results The ITT population consisted of 453 patients randomized to letrozole group and 454 randomized to tamoxifen with groups well-balanced in terms of demographic and background characteristics (Table 1). Most patients experienced at least one adverse event during treatment. Adverse events related to study drug were reported by 38% of patients on letrozole and 37% on tamoxifen, and types of adverse events were similar. After a median follow-up of 32 months, 52 (11%) remained on first-line letrozole and 239 (53%) had crossed over to tamoxifen. In the tamoxifen group, only 27 (6%) remained on first-line tamoxifen and 228 (5%) had switched to letrozole. As previously reported, TTP was 9.4 months in patients taking letrozole first-line compared with 6 months in patients treated with tamoxifen (P <.1). A significant improvement in survival had been seen in the group randomized to letrozole over the first 2 years of the study. However, by end of follow-up, median overall survival was not significantly different (34 months for letrozole versus 3 months for tamoxifen). Table 2 shows mean durations of the TOX, TWiST and PROG health states and differences between treatments in Q-TWiST for the ITT population. Figure 1 displays the partitioned survival plots for letrozole and tamoxifen groups. No significant difference was detected between the letrozole (A) and tamoxifen (B) groups in time spent with toxicity (P =.3). Time without evidence of progression or treatment toxicity was, however, longer in the letrozole group compared with the tamoxifen group (11.5 versus 8.5 months, respectively; P<.1). The mean duration of PROG was 11.5 months for letrozole and 12.7 months for tamoxifen (P =.47). When utility weights for the TOX and PROG health states were set equal to.5, there was a 2.5-month difference in Table 1. Baseline patient characteristics Letrozole (n = 453) Median age (years) Stage IV disease (%) Karnofsky score <8 (%) Soft tissue lesions (%) Bone metastases (%) 54 5 Prior chemotherapy (%) 3 34 Tamoxifen (n = 454)
3 146 Table 2. Mean duration of health states (months) and differences between treatments Health state Letrozole (n = 453) Tamoxifen (n = 454) Difference P value TOX (severe adverse events) TWiST <.1 PROG Q-TWiST a <.1 TOX (attributable adverse events) TWiST PROG Q-TWiST a TOX (all adverse <.1 events) TWiST PROG Q-TWiST a <.1 a Q-TWiST when u TOX = u PROG =.5. TOX, time with toxicity; TWiST, time without toxicity or disease progression; PROG, disease progression; Q-TWiST, quality-adjusted time without symptoms or toxicity. quality-adjusted survival favoring letrozole over tamoxifen (18.4 versus 15.8 months, respectively; P <.1). Q-TWiST was significantly different between the treatments in favor of letrozole across the entire matrix of utility weights, with the differences in quality-adjusted life ranging from just under 2 months to 3 months (Figure 2). Results were similar in sensitivity analyses with varying definitions of the TOX health state (Table 2). When attributable adverse events were considered, patients on letrozole experienced 1.3 more months with adverse events than patients on tamoxifen (P =.6). However, since letrozole extended their TTP, they also experienced 1.9 months longer without symptoms or adverse events prior to disease progression (P =.2). When all adverse events were included in TOX, patients on letrozole experienced 9.4 months in TOX versus 7.2 months for patients on tamoxifen (P <.1). Despite the longer TOX period when low-grade adverse events are included, letrozole resulted in a significantly longer duration of time without progression or toxicity (1 month) and significantly longer quality-adjusted survival across all ranges of utility values, except where the utility for the TOX state <.5 and utility for relapse >.2 (Figure 3). For these extreme utility weights, there was no significant difference between treatments. Discussion Time with severe or life-threatening adverse events was not significantly different between groups, but time without progression or toxicity was significantly longer for letrozole than for tamoxifen. These results closely reflect the TTP analysis reported by Mouridsen et al. [7, 8], but offer additional information about the trade-off between toxicities and delayed A Patients (%) TOX TWIST PROG Days B Patients (%) TOX TWIST PROG Days Figure 1. Partitioned survival plots. For each treatment group, the overall survival time is partitioned into three periods [time with toxicity (TOX), time without symptoms or toxicity (TWiST) and time after progression (PROG)].
4 1461 Utility for toxicity disease progression. The approach used here mimics the way patients and physicians evaluate treatment options through assessing both the total expected survival and the quality of health during that survival period. Regardless of how the health states were weighted, patients experienced the equivalent of 2 3 months longer quality-adjusted survival with letrozole as first-line therapy compared with tamoxifen Utility for relapse Figure 2. Utility threshold plot (primary analysis). This figure indicates statistically significant differences between treatments across the entire matrix of utility weight combinations. Vertical axis is utility for periods of toxicity (u TOX ) and horizontal axis is utility associated with period after disease progression (u PROG ). Line on the graph corresponds to number of months difference between treatments in quality-adjusted survival (letrozole tamoxifen). The difference is 2 months when utilities for time with toxicity (TOX) and progression are both set to.5. Utility for toxicity Utility for relapse Figure 3. Utility threshold plot (sensitivity analysis when all adverse events are included). This figure shows that differences between treatments are not significant when the time with toxicity (TOX) period is rated as having low utility and the period after disease progression is rated as having high utility (bottom right-hand corner, dark gray shading). For other combinations of utility weights, letrozole provides 1 3 months more quality-adjusted survival than tamoxifen. +1 The robustness of this result was confirmed in sensitivity analyses, where additional adverse events were included in the definition of toxicity. In these analyses, the longer duration of time without disease progression or toxicities with letrozole compensated for time with toxicity related to adverse events, especially when the quality of life or utility associated with toxicity is weighted similarly or greater than utility associated with progression. This weighting scheme is a reasonable proxy for patients anticipation of cancer treatment, especially for advanced-stage disease, i.e. for some patients, various adverse events are tolerable and accepted as the trade-off for delayed disease progression. For this same study, Mouridsen et al. [8] report that there was a survival advantage for patients randomized to letrozole in the first 2 years of treatment, although there was no overall difference in survival by the end of follow-up. The lack of statistical difference in overall survival could be attributed to the effects of subsequent treatment after switching to alternate treatment had occurred. Indeed, if second-line therapies were used following the randomized therapy and one was more effective, this could reduce the likelihood of detecting differences in overall survival. The analysis we conducted showed a significant advantage in quality-adjusted survival when letrozole is given as first-line treatment. There are limitations to the assignment of relative utilities as opposed to direct elicitation of quality of life scores from patients. Specifically, some drug effects may not be reportable as adverse events but could affect patient quality of life. Models to incorporate actual quality of life measures into the Q-TWiST framework are being developed, but they are complicated by the usual problem of incomplete data from longitudinal assessments [9]. One recent Q-TWiST approach used changes in quality of life scores as transition points between health states [1]. However, since patient quality of life scores were not elicited during this trial, we provide a comprehensive view of when and how one treatment strategy may be preferred by examining treatment comparisons across the whole range of possible utilities. Further analyses showed that any effects of letrozole would have to compromise quality of life by 4% during the period between toxicities and progression to reverse the treatment difference. This analysis shows that irrespective of how patients value periods of toxicity, a treatment strategy using letrozole offers patients significantly more quality-adjusted survival than tamoxifen. References 1. Gelber RD, Goldhirsch A, Cavalli F, for the International Breast Cancer Study Group. Quality-of-life adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 1991; 114: Gelber RD, Goldhirsch A, Cole BF, for the International Breast Cancer Study Group. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. Control Clin Trials 1993; 14: Gelber RD, Goldhirsch A, Cole BF. Evaluation of effectiveness: Q-TWiST. Cancer Treat Rev 1993; 19: (Suppl A)
5 Gelber RD, Goldhirsch A, for the Ludwig Breast Study Group. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 1986; 4: Goldhirsch A, Gelber RD, Simes RJ et al. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. J Clin Oncol 1989; 7: Glasziou PP, Simes RJ, Gelber RD. Quality-adjusted survival analysis. Stat Med 199; 9: Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. J Clin Oncol 21; 19: Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 23; 21: Mounier N, Ferme C, Fletchner H et al. Model-based methodology for analyzing incomplete quality-of-life data and integrating them into the Q-TWiST framework. Med Decis Making 23; 23: Cole BF, Gelber RD, Gelber S, Mukhopadhyay P. A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J Biopharm Stat 24; 14:
Article 0020.R1/903122
Journal of Medical Economics Vol. 17, No. 5, 2014, 338 346 1369-6998 Article 0020.R1/903122 doi:10.3111/13696998.2014.903122 All rights reserved: reproduction in whole or part not permitted Original article
More informationGiuseppe Viale for the BIG 1 98 Collaborative and International Breast Cancer Study Groups
Central Review of ER, PgR and HER2 in BIG 1 98 Evaluating Letrozole vs. Letrozole Tamoxifen vs. Tamoxifen Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor Positive
More informationYONDELIS (TRABECTEDIN) FOR THE TREATMENT OF SOFT TISSUE SARCOMA. RESPONSE TO EVIDENCE REVIEW GROUP QUERIES (15 th April 2009)
YONDELIS (TRABECTEDIN) FOR THE TREATMENT OF SOFT TISSUE SARCOMA RESPONSE TO EVIDENCE REVIEW GROUP QUERIES (15 th April 2009) 24 th APRIL 2009 Trabectedin for the treatment of advanced metastatic soft tissue
More information4. Aflibercept showed significant improvement in overall survival (OS), the primary
Cost effectiveness of aflibercept (Zaltrap ) in combination with FOLFIRI in the treatment of adult patients with metastatic colorectal cancer (mcrc) that is resistant to or has progressed after an oxaliplatin
More informationTechnology appraisal guidance Published: 20 December 2017 nice.org.uk/guidance/ta496
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor- positive, HER2-negative, e, locally advanced or metastatic breast cancer Technology appraisal guidance Published: 20 December
More informationEverolimus for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT
for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT Thank you very much for the opportunity to submit additional analysis in relation to the above technology appraisal
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationNCCP Chemotherapy Protocol
Letrozole Monotherapy INDICATIONS FOR USE: INDICATION Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer. Extended adjuvant treatment of hormone-dependentinvasive
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer February 1, 2018
pan-canadian Oncology Drug Review Final Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer February 1, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is
More informationCost-effectiveness of osimertinib (Tagrisso )
Cost-effectiveness of osimertinib (Tagrisso ) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationATAC Trial. 10 year median follow-up data. Approval Code: AZT-ARIM-10005
ATAC Trial 10 year median follow-up data Approval Code: AZT-ARIM-10005 Background FDA post-approval commitment analysis to update DFS, TTR, OS and Safety Prof. Jack Cuzick on behalf of ATAC/LATTE Trialists
More informationAdjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial
Adjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial Xin Huang 1 and Qiang (Casey) Xu 2 1 Pfizer Oncology
More informationBackground 1. Comparative effectiveness of nintedanib
NCPE report on the cost effectiveness of nintedanib (Vargatef ) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung
More informationReDOS Trial Background
Regorafenib Dose Optimization Study (ReDos) A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mcrc) Abstract
More informationTechnology appraisal guidance Published: 27 June 2012 nice.org.uk/guidance/ta257
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the firstline treatment of metastatic hormone- receptor-positive e breast cancer that overexpresses HER2 Technology appraisal guidance
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationSetting The study setting was secondary care. The economic study was carried out in Norway.
Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast
More informationIbrutinib for the treatment of relapsed or refractory mantle cell lymphoma (MCL)
Ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma (MCL) Post consultation appraisal committee meeting Dr Jane Adam 2 nd November 2017 Slides for Projector and Public 1 Preliminary
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationTechnology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta239
Fulvestrant for the treatment of locally advanced or metastatic breast cancer Technology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta239 NICE 2018. All rights reserved. Subject
More informationQOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors
QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors Abstract C-33 Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationClinical Trial Results Database Page 1
Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study
More informationClinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
ORIGINAL ARTICLE 2018 Mar 16. [Epub ahead of print] Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Mi Hwa Heo, Hee Kyung Kim,
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationSlides for Committee CIC redacted
Chair s presentation Ribociclib in combination with an aromatase inhibitor for previously untreated advanced or metastatic hormone receptor-positive, HER2-negative breast cancer 3rd Appraisal Committee
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationMONALESSA-7: Phase III placebo-controlled study of ribociclib and tamoxifen/nsai + goserelin
First-line ribociclib or placebo combined with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer:
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationDevelopment of restricted mean survival time difference in network metaanalysis based on data from MACNPC update.
Development of restricted mean survival time difference in network metaanalysis based on data from MACNPC update. Claire Petit, Pierre Blanchard, Jean-Pierre Pignon, Béranger Lueza June 2017 CONTENTS Context...
More informationvemurafenib 240mg film-coated tablet (Zelboraf ) SMC No. (792/12) Roche Products Ltd.
Resubmission vemurafenib 240mg film-coated tablet (Zelboraf ) SMC No. (792/12) Roche Products Ltd. 08 November 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationSCIENTIFIC DISCUSSION
Product name: VELCADE Procedure No. EMEA/H/C/539/II/05 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel:(44-20) 74 18 84, fax (44-20) 74 18 86 68 E-mail: mail@emea.eu.int,
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Everolimus (Afinitor) for Advanced Breast Cancer March 25, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Everolimus (Afinitor) for Advanced Breast Cancer March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationScottish Medicines Consortium
Scottish Medicines Consortium anastrozole 1mg tablets (Arimidex ) No. (198/05) AstraZeneca UK Ltd New indication: for adjuvant treatment of postmenopausal women with hormone receptorpositive early invasive
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationThe NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE do not recommend reimbursement of pertuzumab.
Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous
More informationTechnology appraisal guidance Published: 25 May 2016 nice.org.uk/guidance/ta391
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxelel Technology appraisal guidance Published: 25 May 2016 nice.org.uk/guidance/ta391 NICE 2017. All rights reserved. Subject
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationCHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials
CHL 5225 H Advanced Statistical Methods for Clinical Trials Two sources for course material 1. Electronic blackboard required readings 2. www.andywillan.com/chl5225h code of conduct course outline schedule
More informationSetting The setting was secondary care. The economic study was carried out in Canada.
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis Rocchi A, Verma S Record Status This is a critical
More informationBeyond the intention-to treat effect: Per-protocol effects in randomized trials
Beyond the intention-to treat effect: Per-protocol effects in randomized trials Miguel Hernán DEPARTMENTS OF EPIDEMIOLOGY AND BIOSTATISTICS Intention-to-treat analysis (estimator) estimates intention-to-treat
More informationScottish Medicines Consortium
Scottish Medicines Consortium lenalidomide, 5mg,10mg,15mg and 25mg capsules (Revlimid) No. (441/08) Celgene Europe Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment of
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationAdjuvant Endocrine Therapy: How Long is Long Enough?
Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to
More informationThe Cardiac Arrythmia Suppression Trial
The Cardiac Arrythmia Suppression Trial 1 The Cardiac Arrythmia Suppression Trial Background and significance Methods Statistical Analysis Results Discussion Summary on Therapy 2 Background and significance
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationProduct: Darbepoetin alfa Clinical Study Report: Date: 22 August 2007 Page 2 of 14145
Date: 22 ugust 2007 Page 2 of 14145 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C, US Name of Finished Product: ranesp Name of ctive Ingredient: Darbepoetin alfa Title of Study: Randomized,
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/04/900. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2. Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Phase
More informationQamar J. Khan Bruce F. Kimler Pavan S. Reddy Priyanka Sharma Jennifer R. Klemp Carol J. Fabian
The VITAL trial Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole. Qamar J. Khan Bruce F. Kimler Pavan
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON MISSING DATA
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 CPMP/EWP/1776/99 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO
More informationCritical Reviews in Oncology/Hematology 33 (2000)
Critical Reviews in Oncology/Hematology 33 (2000) 99 103 www.elsevier.com/locate/critrevonc Assessing the relative costs of standard open surgery and laparoscopic surgery in colorectal cancer in a randomised
More informationSUMMARY OF THE SIRFLOX RESULTS
SUMMARY OF THE SIRFLOX RESULTS The SIRFLOX study results on the combination of SIR-Spheres Y-90 resin microspheres with first-line chemotherapy were published in Journal of Oncology in early 2016. 1 There
More informationBevacizumab added to a taxane for the first-line treatment of metastatic breast cancer
Appendix I Bevacizumab added to a taxane for the first-line treatment of metastatic breast cancer Primary Care Trusts (PCTs) provide a unique perspective on the technology, which is not typically available
More informationExtended Adjuvant Endocrine Therapy
Extended Adjuvant Endocrine Therapy After all, 5 years Tamoxifen works.. For women with ER+ primary breast cancer, previous studies have shown that treatment with tamoxifen for 5 years has a carry-over
More informationpan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017
pan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017 DISCLAIMER Not a Substitute for Professional Advice This report
More informationEconomics evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer Neymark N, Lianes P, Smit E F, van Meerbeeck J P
Economics evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer Neymark N, Lianes P, Smit E F, van Meerbeeck J P Record Status This is a critical abstract of an economic
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationHow to carry out health technology appraisals and guidance. Learning from the Scottish experience Richard Clark, Principal Pharmaceutical
The Managed Introduction of New Medicines How to carry out health technology appraisals and guidance. Learning from the Scottish experience Richard Clark, Principal Pharmaceutical Analyst July 10 th 2009,
More informationMEET MARY KISQALI PATIENT PROFILES
KISQALI PATIENT PROFILES MEET MARY Mary was recently diagnosed with HR+/HER2- metastatic breast cancer Review the data from the MONALEESA-2 trial to see how patients like Mary responded The patient profile
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer Resubmission November 21, 2016
pan-canadian Oncology Drug Review Final Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer Resubmission November 21, 2016 DISCLAIMER Not a Substitute for Professional Advice This
More informationReal-world observational data in costeffectiveness analyses: Herceptin as a case study
Real-world observational data in costeffectiveness analyses: Herceptin as a case study DR BONNY PARKINSON, PROFESSOR ROSALIE VINEY, ASSOCIATE PROFESSOR STEPHEN GOODALL AND PROFESSOR MARION HAAS ISPOR AUSTRALIA
More informationSetting The setting was secondary care. The economic study was carried out in the UK.
Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer Robinson P, von der Masse H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D
More informationHuman leukocyte antigen (HLA) system
Is HLA a determinant of prognosis or therapeutic response to cytokines, IFN and anti-ctla4 blocking antibodies in melanoma? Helen Gogas, M.D. Ass. Professor in Medical Oncology 1st Department of Medicine,
More informationLetrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
The new england journal of medicine original article Therapy Alone or in Sequence with in Women with Breast Cancer The BIG 1-98 Collaborative Group* Abstract The members of the writing committee (Henning
More informationScottish Medicines Consortium
Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish
More informationRole of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationSupport for Acetaminophen 1000 mg Over-the-Counter Dose:
Support for Acetaminophen 1000 mg Over-the-Counter Dose: The Dental Impaction Pain Model and Efficacy and Safety Results from McNeil Randomized, Double-Blind, Single-Dose Study of Acetaminophen 1000 mg,
More informationStatistical Analysis Plan (SAP)
Statistical Analysis Plan (SAP) Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax in Ethiopia: a randomized controlled trial Contents
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationMedical Treatment of Early Breast Cancer
J KMA Pharmacotherapeutics Medical Treatment of Early Breast Cancer Soon beom Kang, MD Department of Obstetrics & Gynecology, Seoul National University College of Medicine E mail : ksboo308@plaza.snu.ac.kr
More informationFOR PREVIOUSLY UNTREATED ADVANCED OR METASTATIC ASSUMPTIONS. August 2017
RIBOCICLIB IN COMBINATION WITH AN AROMATOSE INHIBITOR FOR PREVIOUSLY UNTREATED ADVANCED OR METASTATIC HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER: A REVIEW OF THE MODEL STRUCTURE, INPUTS AND
More informationTechnology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380
Panobinostat for treating multiple myeloma after at least 2 previous treatments Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380 NICE 2017. All rights reserved. Subject
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationReview. A. Di Leo 1 *, M. Buyse 2 & H. Bleiberg 1. Introduction. Design and main results of the trials
Review Annals of Oncology 15: 545 549, 2004 DOI: 10.1093/annonc/mdh127 Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical
More informationTechnology appraisal guidance Published: 23 April 2014 nice.org.uk/guidance/ta310
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer Technology appraisal guidance Published: 23 April 2014 nice.org.uk/guidance/ta310
More informationHydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationSummary Background 1. Comparative effectiveness of ramucirumab
Cost-effectiveness of ramucirumab (Cyramza ) for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression following previous treatment
More informationManagement of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers
Review Article Page 1 of 10 Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers Roger K. C. Ngan Department of Clinical Oncology, Queen Elizabeth
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 30 OCTOBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating
More informationVinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Original article Annals of Oncology 14: 699 703, 2003 DOI: 10.1093/annonc/mdg199 Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018
pan-canadian Oncology Drug Review Final Economic Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Advil / Ibuprofen
More informationClinical Policy: Everolimus (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63
Clinical Policy: (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63 Effective Date: 01/18 Last Review Date: Coding Implications Revision Log Description The intent of the criteria is to ensure
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More information